



[www.MedChemExpress.com](http://www.MedChemExpress.com)









Inhibitors, Screening Libraries, Proteins

# Thrombin

Thrombin is a  $\text{Na}^+$ -activated, serine protease which is activated by the enzymatic cleavage of two sites on prothrombin by activated Factor X. Thrombin exists in two allosteric forms, slow (S) and fast (F), target toward anticoagulant and procoagulant activities.

Thrombin is the main effector protease in primary hemostasis by activating platelets and plays a key role in secondary hemostasis. Besides its well-known functions in hemostasis, thrombin also plays a role in various non-hemostatic biological and pathophysiologic processes, predominantly mediated through activation of protease-activated receptors (PARs). PAR-1, PAR-3, and PAR-4 are cleaved by thrombin, whereas PAR-2 is cleaved by trypsin. Thrombin also plays a crucial role in the migration and metastasis of human cancer cells.

## Thrombin Inhibitors, Agonists, Antagonists & Activators


<p><b>AESBF hydrochloride</b></p> <p>Cat. No.: HY-12821</p>	<p><b>Argatroban</b> (MD-805; MCI-9038; Argipidine)</p> <p>Cat. No.: HY-B0375</p>
<p>AESBF hydrochloride is an irreversible inhibitor of <b>serine proteases</b>, such as chymotrypsin, kallikrein, plasmin, thrombin, and trypsin.</p>  <p>Purity: 99.90%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10 mM × 1 mL, 100 mg, 200 mg</p>	<p>Argatroban (MD-805) is a direct, selective thrombin inhibitor.</p>  <p>Purity: &gt;98%</p> <p>Clinical Data: Launched</p> <p>Size: 1 mg, 5 mg</p>
<p><b>Argatroban monohydrate</b> (MD-805 monohydrate; MCI-9038 monohydrate; Argipidine monohydrate)</p> <p>Cat. No.: HY-B0375A</p>	<p><b>Argatroban-d3</b></p> <p>Cat. No.: HY-B0375S</p>
<p>Argatroban (monohydrate) (MD-805 (monohydrate)) is a direct, selective thrombin inhibitor.</p>  <p>Purity: 99.96%</p> <p>Clinical Data: Launched</p> <p>Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg</p>	<p>Argatroban-d3 is the deuterium labeled Argatroban. Argatroban (MD-805) is a direct, selective thrombin inhibitor.</p>  <p>Purity: &gt;98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 10 mg</p>
<p><b>Atecegatran metoxil</b> (AZD0837; Atecegatran fexenetil)</p> <p>Cat. No.: HY-10273</p>	<p><b>BAY 1217224</b></p> <p>Cat. No.: HY-142661</p>
<p>Atecegatran metoxil is an oral anticoagulant, which inhibits <b>thrombin factor II</b> and is used in thromboembolic disorders. In vivo, Atecegatran metoxil is converted to AR-H067637, a selective and reversible direct <b>thrombin</b> inhibitor.</p>  <p>Purity: &gt;98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>BAY 1217224 is a neutral, non-prodrug <b>Thrombin</b> inhibitor with good oral pharmacokinetics.</p>  <p>Purity: &gt;98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p><b>Bivalirudin</b></p> <p>Cat. No.: HY-P1929</p>	<p><b>Bivalirudin TFA</b></p> <p>Cat. No.: HY-15664</p>
<p>Bivalirudin, a peptide anticoagulant, is a direct <b>thrombin</b> inhibitor for anticoagulation in the setting of invasive cardiology, particularly percutaneous coronary intervention.</p> <p>(d-Phe)-PRPGGGGNGDFEIEPEEYL</p> <p>Purity: &gt;98%</p> <p>Clinical Data: Launched</p> <p>Size: 1 mg, 5 mg</p>	<p>Bivalirudin TFA is a synthetic 20 residue peptide which reversibly inhibits thrombin.</p> <p>(d-Phe)-PRPGGGGNGDFEIEPEEYL (TFA salt)</p> <p>Purity: 99.89%</p> <p>Clinical Data: Launched</p> <p>Size: 10 mg, 50 mg, 100 mg</p>
<p><b>Dabigatran</b> (BIBR 953; BIBR 953ZW)</p> <p>Cat. No.: HY-10163</p>	<p><b>Dabigatran (ethyl ester)</b></p> <p>Cat. No.: HY-17378</p>
<p>Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct <b>thrombin</b> inhibitor (<math>K_i=4.5</math> nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (<math>IC_{50}=10</math> nM).</p>  <p>Purity: 98.65%</p> <p>Clinical Data: Phase 4</p> <p>Size: 5 mg, 10 mg, 50 mg, 100 mg</p>	<p>Dabigatran ethyl ester is an emerging oral anticoagulant which is a direct inhibitor of thrombin activity. <math>IC_{50}</math> value: Target: thrombin. Dabigatran provides a stable anticoagulation effect without any need to perform periodical laboratory controls.</p>  <p>Purity: <math>\geq 98.0\%</math></p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>

<p><b>Dabigatran etexilate</b> (BIBR 1048)</p>	<p><b>Dabigatran etexilate mesylate</b> (BIBR 1048MS; Dabigatran etexilate methanesulfonate)</p>
<p>Dabigatran etexilate (BIBR 1048) is an orally active prodrug of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation.</p> <p><b>Purity:</b> 99.75% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>	<p>Dabigatran etexilate mesylate (BIBR 1048MS) is an orally active prodrug of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate mesylate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation.</p> <p><b>Purity:</b> 99.60% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg</p>
<p><b>Dabigatran ethyl ester hydrochloride</b></p>	<p><b>Dabigatran ethyl ester-d3 hydrochloride</b></p>
<p>Dabigatran ethyl ester hydrochloride is a potent inhibitor of ribosyldihydrnicotinamide dehydrogenase (NQO2) with an IC<sub>50</sub> value of 0.8 μM and a <b>thrombin</b> inhibitor.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>Dabigatran ethyl ester-d3 hydrochloride is the deuterium labeled Dabigatran (ethyl ester hydrochloride).</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Dabigatran-13C,d3</b> (BIBR 953-13C,d3; BIBR 953ZW-13C,d3)</p>	<p><b>Dabigatran-d3</b> (BIBR 953-d3; BIBR 953ZW-d3)</p>
<p>Dabigatran-13C,d3 is the 13C- and deuterium labeled. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (K<sub>i</sub>=4.5 nM).</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p>Dabigatran-d3 (BIBR 953-d3) is the deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct <b>thrombin</b> inhibitor (K<sub>i</sub>=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC<sub>50</sub>=10 nM).</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>
<p><b>Dabigatran-d4</b> (BIBR 953-d4; BIBR 953ZW-d4)</p>	<p><b>Dabigatran-d4 hydrochloride</b> (BIBR-953-d4 hydrochloride)</p>
<p>Dabigatran-d4 is deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (K<sub>i</sub>=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC<sub>50</sub>=10 nM).</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p>Dabigatran (BIBR-953) D4 hydrochloride is deuterium labeled Dabigatran, which is a reversible and selective, direct thrombin inhibitor (DTI) with a K<sub>i</sub> value of 4.5 nM.</p> <p><b>Purity:</b> &gt;98.0% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg</p>
<p><b>Desethyl KBT-3022</b></p>	<p><b>Edoxaban</b> (DU-176)</p>
<p>Desethyl KBT-3022 is the main active metabolite of the new antiplatelet agent, KBT-3022.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p>	<p>Edoxaban (DU-176) is a selective, potent and orally active <b>factor Xa (FXa)</b> inhibitor with K<sub>i</sub>s of 0.561 nM and 2.98 nM for <b>free FXa</b> and <b>prothrombinase</b>, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention.</p> <p><b>Purity:</b> 99.59% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>

### Edoxaban impurity 4

Cat. No.: HY-134686

Edoxaban impurity 4 is an impurity of Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active **factor Xa (FXa)** inhibitor with  $K_s$  of 0.561 nM and 2.98 nM for **free FXa** and **prothrombinase**, respectively.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 5 mg, 10 mg

### Edoxaban tosylate

(DU-176b)

Cat. No.: HY-10264A

Edoxaban tosylate (DU-176b) is a selective, potent and orally active **factor Xa (FXa)** inhibitor with  $K_s$  of 0.561 nM and 2.98 nM for **free FXa** and **prothrombinase**, respectively. Edoxaban tosylate is an anticoagulant agent and can be used for stroke prevention.




**Purity:** 99.47%  
**Clinical Data:** Launched  
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### Edoxaban tosylate monohydrate

(DU-176b monohydrate)

Cat. No.: HY-10264B

Edoxaban tosylate monohydrate (DU-176b monohydrate) is a selective, potent and orally active **factor Xa (FXa)** inhibitor with  $K_s$  of 0.561 nM and 2.98 nM for **free FXa** and **prothrombinase**, respectively.




**Purity:** 99.95%  
**Clinical Data:** Launched  
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### Edoxaban-d6

(DU-176-d6)

Cat. No.: HY-10264S

Edoxaban-d6 is deuterium labeled Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active **factor Xa (FXa)** inhibitor with  $K_s$  of 0.561 nM and 2.98 nM for **free FXa** and **prothrombinase**, respectively.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

### Heparin

Cat. No.: HY-17567

Heparin is a highly sulfated glycosaminoglycan, that is widely used as an injectable anticoagulant, and has the highest negative charge density of any known biological molecule. Heparin significantly inhibits exosome-cell interactions.




**Purity:** >98%  
**Clinical Data:** Launched  
**Size:** 10 mg (10 mg × mL in Water)

### Heparin Lithium salt

Cat. No.: HY-17567B

Heparin Lithium salt is an anticoagulant which binds reversibly to **antithrombin III (ATIII)**. Heparin Lithium salt significantly inhibits exosome-cell interactions.




**Purity:** >98%  
**Clinical Data:** Launched  
**Size:** 10 mg (10 mg × mL in Water), 100 mg, 500 mg

### Heparin sodium salt

(Sodium heparin; Sodium heparinate)

Cat. No.: HY-17567A

Heparin sodium salt (Sodium heparin) is an anticoagulant which binds reversibly to **antithrombin III (ATIII)** and greatly accelerates the rate at which ATIII inactivates coagulation enzymes **thrombin factor IIa** and **factor Xa**.




**Purity:** >98%  
**Clinical Data:** Launched  
**Size:** 100 mg, 500 mg, 1 g

### Heparin sodium salt (MW 15kDa)

(Sodium heparin (MW 15kDa); Sodium heparinate (MW 15kDa)) Cat. No.: HY-17567C

Heparin sodium salt (MW 15kDa) (Sodium heparin (MW 15kDa)) is a polymer of Heparin with the molecular weight of 15kDa.




**Purity:** >98%  
**Clinical Data:** Launched  
**Size:** 100 mg, 500 mg

### Idraparinux sodium

(SANORG 34006; SR-34006)

Cat. No.: HY-19691

Idraparinux (sodium) is a polymethylated synthetic pentasaccharide known to interact with the **antithrombin III** and act as anticoagulant.




**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

### Inogatran










(H-314-27)






Cat. No.: HY-19660

Inogatran (H-314-27) is a synthetic **thrombin** inhibitor, developed for the possible treatment and prophylaxis of arterial and venous thrombotic diseases.



**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

<p><b>Melagatran</b></p> <p>Cat. No.: HY-129056</p>	<p><b>Metolazone</b> (SR-720-22)</p> <p>Cat. No.: HY-B0209</p>
<p>Melagatran is a direct and orally active inhibitor of <b>thrombin</b>, without interacting with any other enzymes in the coagulation cascade or fibrinolytic enzymes aside from thrombin.</p> <p></p> <p>Purity: &gt;98% Clinical Data:  Size: 1 mg, 5 mg, 10 mg</p>	<p>Metolazone (SR-720-22) is primarily used to treat congestive heart failure and high blood pressure.</p> <p></p> <p>Purity: 99.86% Clinical Data: Launched Size: 10 mM × 1 mL, 50 mg, 100 mg</p>
<p><b>Metolazone-d7</b> (SR-720-22-d7)</p> <p>Cat. No.: HY-B0209S</p>	<p><b>Napsagatran hydrate</b> (Ro 46-6240 hydrate; Ro 46-6240/010 hydrate)</p> <p>Cat. No.: HY-15759A</p>
<p>Metolazone-d7 is deuterium labeled Metolazone. Metolazone (SR-720-22) is primarily used to treat congestive heart failure and high blood pressure.</p> <p></p> <p>Purity: &gt;98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Napsagatran hydrate is a novel and specific <b>thrombin</b> inhibitor.</p> <p></p> <p>Purity: &gt;98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p><b>NQ301</b></p> <p>Cat. No.: HY-101054</p>	<p><b>Odiparcil</b> (SB-424323)</p> <p>Cat. No.: HY-10277</p>
<p>NQ301 is an antithrombotic agent; inhibits collagen-challenged rabbit platelet aggregation with an <math>IC_{50}</math> of 10 mg/mL.</p> <p></p> <p>Purity: 98.12% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>Odiparcil (SB-424323) is an orally active beta-d-thioxyloside analog with antithrombotic activity associated with a reduced risk of adverse bleeding events.</p> <p></p> <p>Purity: ≥99.0% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p><b>OM-189</b></p> <p>Cat. No.: HY-100245</p>	<p><b>Protamine sulfate</b></p> <p>Cat. No.: HY-107911</p>
<p>OM-189 is a selective synthetic <b>thrombin</b> inhibitor.</p> <p></p> <p>Purity: &gt;98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Protamine sulfate, polycationic peptide and a antiheparin agent, could neutralize the anticoagulant action of heparin and enhances lipid-mediated gene transfer.</p> <p><b>Protamine sulfate</b></p> <p>Purity: &gt;98% Clinical Data: Launched Size: 100 mg</p>
<p><b>Razaxaban hydrochloride</b> (BMS 561389 hydrochloride; DPC 906 hydrochloride)</p> <p>Cat. No.: HY-11091</p>	<p><b>RWJ-445167</b> (3DP-10017)</p> <p>Cat. No.: HY-19373</p>
<p>Razaxaban hydrochloride (BMS 561389 hydrochloride) is a highly potent, selective and orally active <b>factor Xa</b> inhibitor with a <math>K_i</math> of 0.19 nM. Razaxaban hydrochloride exhibits excellent selectivity (&gt;5000-fold) for <b>factor Xa</b> over other related serine proteases.</p> <p></p> <p>Purity: &gt;98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>RWJ-445167 (3DP-10017) is a dual inhibitor of <b>thrombin</b> and <b>factor Xa</b> with <math>K_i</math> of 4.0 nM and 230 nM, respectively, exhibiting potent antithrombotic activity.</p> <p></p> <p>Purity: &gt;98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p><b>Sfllrnpndkyepf</b></p> <p>Cat. No.: HY-P1000</p>	<p><b>Sofigatran</b> (MCC-977)</p> <p>Cat. No.: HY-14936</p>
<p>Sfllrnpndkyepf is a synthetic <b>thrombin</b> receptor agonist peptide.</p> <p>SFLLRNPNDKYEPF</p> <p><b>Purity:</b> 97.23%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg, 10 mg</p>	<p>Sofigatran (MCC-977) is an orally active <b>factor IIa (thrombin)</b> inhibitor, acts as an anticoagulant. Sofigatran is used for the research of cardiovascular disease.</p>  <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>
<p><b>Thrombin (MW 37kDa)</b></p> <p>Cat. No.: HY-114164</p>	<p><b>Thrombin inhibitor 1</b></p> <p>Cat. No.: HY-U00370</p>
<p>Thrombin (MW 37kDa) is a Na<sup>+</sup>-activated, allosteric serine protease that plays opposing functional roles in blood coagulation. Thrombin recognition sequence and can be used to digest GST-tagged proteins.</p> <p><b>Thrombin</b></p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> Phase 4</p> <p><b>Size:</b> 1000 U, 2000 U</p>	<p>Thrombin inhibitor 1 is a potent <b>thrombin</b> inhibitor (<math>K_i=0.66</math> nM, 2xaPTT=0.43 <math>\mu</math>M).</p>  <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>
<p><b>Thrombin Inhibitor 2</b></p> <p>Cat. No.: HY-10217</p>	<p><b>TP508</b></p> <p>Cat. No.: HY-P0316</p>
<p>Thrombin Inhibitor 2 is a small molecule direct <b>thrombin</b> inhibitor, extracted from US8541580B2. Thrombin Inhibitor 2 has antithrombotic activity.</p>  <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>	<p>TP508 is a 23-amino acid nonproteolytic <b>thrombin</b> peptide that represents a portion of the receptor-binding domain of thrombin molecule. TP508 activates endothelial <b>NO synthase (eNOS)</b> and stimulates production of NO in human endothelial cells.</p> <p>AGYKPDEGKRGDACEGDSGGPFV</p> <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> Phase 2</p> <p><b>Size:</b> 1 mg, 5 mg</p>
<p><b>TP508 TFA</b></p> <p>Cat. No.: HY-P0316A</p>	<p><b>Ximelagatran</b> (H 376/95)</p> <p>Cat. No.: HY-10787</p>
<p>TP508 TFA is a 23-amino acid nonproteolytic <b>thrombin</b> peptide that represents a portion of the receptor-binding domain of thrombin molecule. TP508 TFA activates endothelial <b>NO synthase (eNOS)</b> and stimulates production of NO in human endothelial cells.</p> <p>AGYKPDEGKRGDACEGDSGGPFV (TFA salt)</p> <p><b>Purity:</b> 99.79%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 5 mg, 10 mg, 50 mg</p>	<p>Ximelagatran (H 376/95) is an orally active <b>thrombin</b> inhibitor that selectively and competitively inhibits both free and clot-bound <b>thrombin</b>.</p>  <p><b>Purity:</b> <math>\geq</math>98.0%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10 mM <math>\times</math> 1 mL, 500 <math>\mu</math>g, 1 mg, 5 mg, 10 mg, 25 mg</p>
<p><b>Ximelagatran-d11</b> (H 376/95-d11)</p> <p>Cat. No.: HY-10787S</p>	
<p>Ximelagatran-d11 (H 376/95-d11) is the deuterium labeled Ximelagatran. Ximelagatran (H 376/95) is an orally active <b>thrombin</b> inhibitor that selectively and competitively inhibits both free and clot-bound <b>thrombin</b>.</p>  <p><b>Purity:</b> &gt;98%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 1 mg, 5 mg</p>	